Reply to Letter to the Editor by Yin et al

Brenda L Coleman^{1

2

3}, Ruth Sanderson¹, Mendel D M Haag⁴, Ian McGovern⁵

Affiliations

¹ Sinai Health System, Toronto, ON, Canada.
² Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
³ Western University, London, ON, Canada.
⁴ Seqirus NL BV, Amsterdam, The Netherlands.
⁵ Seqirus Inc., Cambridge, Massachusetts, USA.

Comment

Brenda L Coleman et al. Influenza Other Respir Viruses. 2021 Nov.

. 2021 Nov;15(6):828-829.

doi: 10.1111/irv.12895. Epub 2021 Aug 10.

Brenda L Coleman^{1

2

3}, Ruth Sanderson¹, Mendel D M Haag⁴, Ian McGovern⁵

¹ Sinai Health System, Toronto, ON, Canada.
² Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
³ Western University, London, ON, Canada.
⁴ Seqirus NL BV, Amsterdam, The Netherlands.
⁵ Seqirus Inc., Cambridge, Massachusetts, USA.

No abstract available

Keywords: influenza; systematic review; vaccines.

Conflict of interest statement

BLC and RS were employed by Sinai Health which received funding from Seqirus for this review. MDMH and IM are employed by Seqirus.

Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta-analysis.
Coleman BL, Sanderson R, Haag MDM, McGovern I. Coleman BL, et al. Influenza Other Respir Viruses. 2021 Nov;15(6):813-823. doi: 10.1111/irv.12871. Epub 2021 Jun 3. Influenza Other Respir Viruses. 2021. PMID: 34081398 Free PMC article.
Letter to editor regarding the systematic review and meta-analysis by Coleman et al. on the effectiveness of MF59-adjuvanted seasonal influenza vaccine in older adults.
Yin JK, Samson SI, Nealon J. Yin JK, et al. Influenza Other Respir Viruses. 2021 Nov;15(6):826-827. doi: 10.1111/irv.12891. Epub 2021 Aug 2. Influenza Other Respir Viruses. 2021. PMID: 34342136 Free PMC article. No abstract available.

1. Coleman BL, Sanderson R, Haag MD, McGovern I. Effectiveness of the MF59‐adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta‐analysis. Influenza Other Respi Viruses. 2021. - PMC - PubMed
1. Yin JK, Samson S, Nealon J. Letter to Editor regarding the systematic review and metaanalysis by Coleman et al. on the effectiveness of MF59‐ adjuvanted seasonal influenza vaccine in older adults. Influenza Other Respi Viruses. 2021. - PMC - PubMed
1. Gasparini R, Amicizia D, Lai PL, Rossi S, Panatto D. Effectiveness of adjuvanted seasonal influenza vaccines (Inflexal V and Fluad) in preventing hospitalization for influenza and pneumonia in the elderly: a matched case‐control study. Hum Vaccin Immunother. 2013;9(1):144‐152. Science.gov, 10.4161/hv.22231 - DOI - PMC - PubMed
1. Systematic review of the efficacy, effectiveness and safety of newer and enhanced seasonal influenza vaccines. (2020). European Centre for Disease Prevention and Control (ECDC) . https://www.ecdc.europa.eu/en/publications-data/seasonal-influenza-syste...
1. Spadea A, Unim B, Colamesta V, et al. Is the adjuvanted influenza vaccine more effective than the trivalent inactivated vaccine in the elderly population? Results of a case–control study. Vaccine. 2014;32(41):5290‐5294. - PubMed